Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | FASN | P49327 | 3/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | WNT3A | P56704 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18321694 | 0.89 | FASN (0.46) | GSK3BFASN | |
| SCHEMBL18321493 | 0.88 | FASN (0.53) | GSK3BFASN | |
| SCHEMBL21628184 | 0.88 | GSK3B (0.45) | GSK3BFASNGPR119PTPN2PTPN1 | |
| SCHEMBL21628187 | 0.86 | GPR119 (0.45) | GSK3BFASNGPR119PTPN2PTPN1 | |
| SCHEMBL18321767 | 0.85 | FASN (0.43) | FASNGPR119PTPN2PTPN1PTPN6 | |
| SCHEMBL18321518 | 0.80 | GSK3B (0.38) | GSK3BFASNMETPOLB | |
| SCHEMBL18321399 | 0.79 | GSK3B (0.45) | GSK3BFASN | |
| SCHEMBL18321674 | 0.77 | FPR2 (0.44) | GPR119PTPN2PTPN1PTPN6USP30 | |
| SCHEMBL18321749 | 0.76 | FASN (0.51) | GSK3BFASN | |
| SCHEMBL18321479 | 0.75 | GSK3B (0.47) | GSK3BFASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441702-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivates | CEPHALON LLC (US) | 2025-10-14 | — | — | US | disclosed |
| US-20240166625-A1 | Substituted 4-Benzyl And 4-Benzoyl Piperidine Derivates | CEPHALON LLC | 2024-05-23 | — | — | US | disclosed |
| US-11878966-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivates | 89BIO LTD (IL) | 2024-01-23 | — | — | US | disclosed |
| US-20220081411-A1 | Substituted 4-Benzyl And 4-Benzoyl Piperidine Derivates | CEPHALON LLC | 2022-03-17 | — | — | US | disclosed |
| US-10919875-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivatives | 89BIO LTD (IL) | 2021-02-16 | — | — | US | disclosed |
| EP-3310773-B1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | 89BIO LTD (IL) | 2020-12-02 | — | — | EP | disclosed |
| US-20200031797-A1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | CEPHALON LLC | 2020-01-30 | — | — | US | disclosed |
| EP-3310773-A1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | Cephalon, Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| WO-2016205590-A1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | CEPHALON, INC. (US) | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441702-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivates | FASN, CES1, FADS2 | GSK3B 3538/4885FASN 1/4885GPR119 253/4885 |
| US-20240166625-A1 | Substituted 4-Benzyl And 4-Benzoyl Piperidine Derivates | FASN, CES1, FADS2 | GSK3B 3538/4885FASN 1/4885GPR119 253/4885 |
| US-20200031797-A1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | FASN, FADS1, ASS1 | GSK3B 3679/4885FASN 1/4885GPR119 294/4885 |
| US-10919875-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivatives | FASN, CES1, FADS2 | GSK3B 3318/4885FASN 1/4885GPR119 250/4885 |
| US-20220081411-A1 | Substituted 4-Benzyl And 4-Benzoyl Piperidine Derivates | FASN, CES1, FADS2 | GSK3B 3538/4885FASN 1/4885GPR119 253/4885 |
| US-11878966-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivates | FASN, CES1, FADS2 | GSK3B 3538/4885FASN 1/4885GPR119 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.